Antheia, a biomanufacturer that makes a key ingredient for the opioid overdose treatment Narcan, reeled in $56 million in a ...

Novartis admitted the email broke several rules set out in the U.K. marketing code. In a long response to the PMCPA, the ...

With those findings in mind, the ABPI recommended in the report that pharmas “explore the appropriate use of social media ...

Agenus, which has been going through a reorganization after the FDA put the brakes on the biotech's regulatory plan for its ...

With the American Society of Clinical Oncology (ASCO) annual meeting in full swing at Chicago’s McCormick Place this past ...

With the deal, Sanofi gains Blueprint’s portfolio of rare immunological disease treatments, including systemic mastocytosis ...

Despite its success in advanced melanoma, Bristol Myers Squibb’s fixed-dose PD-1/LAG-3 combo, Opdualag, failed to move the ...

The FDA has already approved PARP inhibitors in certain patients with metastatic castration-resistant prostate cancer (mCRPC) ...

Though they are both multiple myeloma drugs with the same mechanism of action, Sanofi’s Sarclisa has had difficulty competing ...

Despite uncertainties arising from new FDA policies around COVID-19 vaccines, Moderna has cleared the agency's desk with its ...

Amgen has detailed a positive phase 3 readout for its T-cell engager Imdelltra in previously treated small cell lung cancer ...

With that, Theravance expects its lifetime value from the inhaler to come out to $1.52 billion. The drug stems from a 2002 ...